Yahoo Web Search

Search results

    • Is CRISPR Therapeutics Stock a Buy?

      Is CRISPR Therapeutics Stock a Buy?

      Motley Fool via Yahoo Finance· 14 minutes ago

      The target market for Casgevy isn't huge, at least for now. Vertex and CRISPR estimate that there are about 35,000 eligible patients in the U.S. and...